Company profile for SiSaf

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

SiSaf has developed the Bio-Courier® platform of silicon stabilized hybrid lipid nanoparticles to dramatically improve the stabilization and delivery of RNA based therapeutics and vaccines. We are using its proprietary next-generation hybrid nanoparticles to advance our in-house pipeline of RNA therapeutics for rare genetic skeletal disorders, alongside partnering with specialty pharmaceutical companies to maximize the potent...
SiSaf has developed the Bio-Courier® platform of silicon stabilized hybrid lipid nanoparticles to dramatically improve the stabilization and delivery of RNA based therapeutics and vaccines. We are using its proprietary next-generation hybrid nanoparticles to advance our in-house pipeline of RNA therapeutics for rare genetic skeletal disorders, alongside partnering with specialty pharmaceutical companies to maximize the potential applications of its Bio-Courier platform.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
United Kingdom
Address
Address
3 Huxley Rd, Guildford GU2 7RE, United Kingdom
Telephone
Telephone
+44 1483 912002
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2024/06/10/2895778/0/en/SiSaf-s-Bio-Courier-Technology-Enables-Clinical-Trial-Success-for-Topical-Treatment-of-Mild-to-Moderate-Alopecia-Areata.html

GLOBENEWSWIRE
10 Jun 2024

https://www.globenewswire.com//news-release/2023/09/18/2744460/0/en/Peer-Reviewed-Publication-of-Positive-Preclinical-Data-of-SiSaf-s-SIS-ADO2-siRNA-Program-to-Treat-Rare-Genetic-Bone-Disorder-Osteopetrosis.html

GLOBENEWSWIRE
18 Sep 2023

https://www.globenewswire.com/news-release/2023/07/13/2704085/0/en/SiSaf-Appoints-Nikos-Tzagkarakis-in-the-New-Role-of-Chief-A-I-Officer.html

GLOBENEWSWIRE
13 Jul 2023

https://www.globenewswire.com/news-release/2023/05/15/2668400/0/en/FDA-Grants-SiSaf-s-Innovative-siRNA-Therapy-SIS-101-ADO-Orphan-Drug-Designation-and-Rare-Pediatric-Disease-Designation-for-the-Treatment-of-Autosomal-Dominant-Osteopetrosis.html

GLOBENEWSWIRE
15 May 2023

https://www.globenewswire.com/news-release/2023/04/05/2641367/0/en/SiSaf-Appoints-Dr-Richard-Goodfellow-to-Board-of-Directors.html

GLOBENEWSWIRE
05 Apr 2023

https://www.globenewswire.com/news-release/2023/03/02/2618970/0/en/SiSaf-and-the-University-of-Leipzig-Partner-to-Develop-Bio-Courier-Targeted-miRNA-for-the-Treatment-of-Pancreatic-Cancer.html

GLOBENEWSWIRE
02 Mar 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty